{"version":"1.0","type":"link","title":"Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.","author_name":"Planchard D 외","author_url":"https://prs-insight.online/author/Planchard%20D","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/99924","thumbnail_width":1200,"thumbnail_height":630}